Dr. von Eschenbach named acting FDA commissioner

Article

Urologist Andrew von Eschenbach, MD, director of the National Cancer Institute, has been named by President Bush to assume the role of acting commissioner of the FDA.

Urologist Andrew von Eschenbach, MD, director of the National Cancer Institute, has been named by President Bush to assume the role of acting commissioner of the FDA. The appointment follows the resignation of Lester M. Crawford, DVM, PhD, on Sept. 23.

As director of NCI, Dr. von Eschenbach has been a strong proponent of a more collaborative, team-science approach to research and the movement toward individualized medicine based on the growing understanding of the molecular underpinnings of many diseases, NCI said in a prepared statement.

"When I came to NCI in 2002, I made this our challenge goal: to eliminate the suffering and death due to cancer by 2015," he said. "I will work to ensure that this critically important work continues at NCI, even as the crucial initiatives at FDA continue unabated during this time of transition."

No deadline has been set for appointment of a permanent FDA commissioner.

Related Videos
Marc Bjurlin, DO, MSc, FACOS, answers a question during a Zoom video interview
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
John Michael DiBianco, MD, answers a question during a Zoom video interview
Shaya Taghechian, MD, answers a question during a video interview
Human kidney cross section on science background | Image Credit: © Crystal light - stock.adobe.com
A panel of 4 experts on prostate cancer
Joseph Song, MD, answers a question during a video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.